Best chance to quit smoking. Last chance to win.

Canadian Cancer Society's Driven to Quit Challenge ends February 28

TORONTO, Feb. 19, 2014 /CNW/ - Quitting smoking is the single most important thing someone can do to prevent cancer and there's never been a better time to quit than right now.

February 28 is the final day to register for the Canadian Cancer Society's Driven to Quit Challenge, presented by McNeil Consumer Healthcare, division of Johnson & Johnson Inc., the makers of NICODERM® and NICORETTE®. The Challenge is a campaign to motivate adult Ontario tobacco users to quit smoking or other forms of tobacco for the month of March with the help of a support "buddy" for their chance to win a grand prize of a car and other cash prizes.

"The Driven to Quit Challenge offers great odds of winning because, not only does everyone who registers have a chance at winning the grand prize, they are a winner simply for taking this important step towards improving their health and wellness," says John Atkinson, Director, Tobacco Control and Cancer Prevention. "And with supportive resources such as the Canadian Cancer Society's Smokers' Helpline, the Driven to Quit Challenge helps smokers in Ontario win by inspiring them to quit for good."

Participants who stay smoke-free all month will be eligible to win a choice between a Dodge Avenger or a Dodge Journey or one of seven prizes of $1,000. Support buddies of winners each receive a $100 cash prize.

"We know that many smokers make five to seven attempts before they quit successfully and we want to give all participants the best possible support as they take this important step to a healthier lifestyle," says Krista Scaldwell, Vice-President, Communications and Government Affairs at Johnson & Johnson Inc. "We're committed to helping smokers with clinically proven, safe and effective nicotine replacement products."

Driven to Quit Challenge participants can receive discount coupons towards the purchase of NICODERM® or NICORETTE®. Coupons are available while quantities last.

To register and for more information about The Driven to Quit Challenge, go to www.DrivenToQuit.ca or call the Canadian Cancer Society's Smokers' Helpline at 1-877-513-5333.

About the Driven to Quit Challenge
The Canadian Cancer Society, Ontario Division's Driven to Quit Challenge, presented by McNeil Consumer Healthcare, division of Johnson & Johnson Inc., makers of NICODERM® and NICORETTE®, is a health promotion campaign that is intended to motivate adult Ontario tobacco users to quit smoking or other forms of tobacco for one month with the help of a support "buddy" for their chance to win a grand prize of a car. Participants are encouraged to access Smokers' Helpline and Smokers' Helpline Online for cessation support. To claim a prize, selected winners must demonstrate that they have remained tobacco-free for the month of March 2014.

About the Canadian Cancer Society Smokers' Helpline
Smokers' Helpline is a free, confidential service that provides personalized support, advice and information about quitting smoking and tobacco use. Operated by the Canadian Cancer Society and funded by the Government of Ontario, Smokers' Helpline has three ways to help Ontarians quit: phone support, online program and text messaging at 1-877-513-5333 and SmokersHelpline.ca.

About the Canadian Cancer Society
The Canadian Cancer Society is a national community-based organization of volunteers whose mission is the eradication of cancer and the enhancement of the quality of life of people living with cancer. When you want to know more about cancer, visit our website www.cancer.ca or call our toll-free, bilingual Cancer Information Service at 1 888 939-3333.

About McNeil Consumer Healthcare, division of Johnson & Johnson Inc.
McNeil Consumer Healthcare, division of Johnson & Johnson Inc. markets a broad range of well-known and trusted over-the-counter products. McNeil Consumer Healthcare is most widely recognized for the TYLENOL® brand. Other McNeil Consumer Healthcare brands include NICODERM® and NICORETTE® Nicotine Replacement Therapies,  BENADRYL® and REACTINE® allergy medicines; IMODIUM® anti-diarrheal; PEPCID® and ZANTAC® for digestive health, and  MOTRIN® Ibuprofen.

SOURCE: Canadian Cancer Society (Ontario Division)

For further information:

Media Contact:
Christine Koserski, Communications Specialist
Canadian Cancer Society, Ontario Division
416-323-7030
[email protected]